Proteome Analysis Identified the PPARγ Ligand 15d-PGJ2 as a Novel Drug Inhibiting Melanoma Progression and Interfering with Tumor-Stroma Interaction

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Paulitschke, Verena ^a   Gruber, Silke ^a   Hofstätter, Elisabeth ^a   Haudek Prinz, Verena ^b   Klepeisz, Philipp ^b   Schicher, Nikolaus ^a   Jonak, Constanze ^a   Petzelbauer, Peter ^a   Pehamberger, Hubert ^a   Gerner, Christopher ^b   Kunstfeld, Rainer ^a  

^a Universitatsklinik fur Dermatologie   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; CIGLITAZONE; HEAT SHOCK PROTEIN 90; PIRINIXIC ACID; PROTEIN P21; PROTEOME; TROGLITAZONE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA CELL; MIGRATION INHIBITION; MITOSIS INHIBITION; NEWBORN; P21 GENE; PROTEIN ANALYSIS; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHROMANS; HUMANS; MELANOMA; PPAR GAMMA; PROSTAGLANDIN D2; PROTEOME; PYRIMIDINES; THIAZOLIDINEDIONES;

EID: 84866702312     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046103     Document Type: Article

References (57)

1. Schadendorf D, (2009) Peroxisome proliferator-activating receptors: a new way to treat melanoma? J Invest Dermatol 129: 1061-1063.
2. Smalley KS, Herlyn M, (2005) Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics. Ann N Y Acad Sci 1059: 16-25.
3. Nunez NP, Liu H, Meadows GG, (2006) PPAR-gamma ligands and amino acid deprivation promote apoptosis of melanoma, prostate, and breast cancer cells. Cancer Lett 236: 133-141.
4. Schoonjans K, Martin G, Staels B, Auwerx J, (1997) Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol 8: 159-166.
5. Torra IP, Chinetti G, Duval C, Fruchart JC, Staels B, (2001) Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice. Curr Opin Lipidol 12: 245-254.
6. Kihara S, Ouchi N, Funahashi T, Shinohara E, Tamura R, et al. (1998) Troglitazone enhances glucose uptake and inhibits mitogen-activated protein kinase in human aortic smooth muscle cells. Atherosclerosis 136: 163-168.
7. Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR, (1998) Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 339: 953-959.
8. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, et al. (1998) Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 58: 3344-3352.
9. Mossner R, Schulz U, Kruger U, Middel P, Schinner S, et al. (2002) Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma. J Invest Dermatol 119: 576-582.
10. Liu Y, Meng Y, Liu H, Li J, Fu J, et al. (2006) Growth inhibition and differentiation induced by peroxisome proliferator activated receptor gamma ligand rosiglitazone in human melanoma cell line a375. Med Oncol 23: 393-402.
11. Goetze S, Eilers F, Bungenstock A, Kintscher U, Stawowy P, et al. (2002) PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem Biophys Res Commun 293: 1431-1437.
12. Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, et al. (2002) PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 110: 923-932.
13. Placha W, Gil D, Dembinska-Kiec A, Laidler P, (2003) The effect of PPARgamma ligands on the proliferation and apoptosis of human melanoma cells. Melanoma Res 13: 447-456.
14. Smith AG, Beaumont KA, Smit DJ, Thurber AE, Cook AL, et al. (2009) PPARgamma agonists attenuate proliferation and modulate Wnt/beta-catenin signalling in melanoma cells. Int J Biochem Cell Biol 41: 844-852.
15. Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, et al. (2006) Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res 19: 290-302.
16. Grabacka M, Plonka PM, Urbanska K, Reiss K, (2006) Peroxisome proliferator-activated receptor alpha activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt. Clin Cancer Res 12: 3028-3036.
17. Wimmer H, Gundacker NC, Griss J, Haudek VJ, Stattner S, et al. (2009) Introducing the CPL/MUW proteome database: interpretation of human liver and liver cancer proteome profiles by referring to isolated primary cells. Electrophoresis 30: 2076-2089.
18. Griss J, Haudek-Prinz VJ, Gerner C, (2010) GPDE: A biological proteomics database for biomarker discovery and evaluation. Proteomics.
19. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ, (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816.
20. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, et al. (1993) p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704.
21. Paulitschke V, Schicher N, Szekeres T, Jager W, Elbling L, et al. (2009) 3,3′,4,4′,5,5′-Hexahydroxystilbene Impairs Melanoma Progression in a Metastatic Mouse Model. J Invest Dermatol.
22. Fievet C, Staels B, (2009) Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease. Curr Atheroscler Rep 11: 281-288.
23. Bensinger SJ, Tontonoz P, (2008) Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 454: 470-477.
24. Lee TS, Tsai HL, Chau LY, (2003) Induction of heme oxygenase-1 expression in murine macrophages is essential for the anti-inflammatory effect of low dose 15-deoxy-Delta 12,14-prostaglandin J2. J Biol Chem 278: 19325-19330.
25. Grommes C, Landreth GE, Sastre M, Beck M, Feinstein DL, et al. (2006) Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment. Mol Pharmacol 70: 1524-1533.
26. Galli A, Ceni E, Crabb DW, Mello T, Salzano R, et al. (2004) Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms. Gut 53: 1688-1697.
27. Ferruzzi P, Ceni E, Tarocchi M, Grappone C, Milani S, et al. (2005) Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. J Clin Endocrinol Metab 90: 1332-1339.
28. Shen D, Deng C, Zhang M, (2007) Peroxisome proliferator-activated receptor gamma agonists inhibit the proliferation and invasion of human colon cancer cells. Postgrad Med J 83: 414-419.
29. Bundscherer A, Reichle A, Hafner C, Meyer S, Vogt T, (2009) Targeting the tumor stroma with peroxisome proliferator activated receptor (PPAR) agonists. Anticancer Agents Med Chem 9: 816-821.
30. Prakash J, Bansal R, Post E, de Jager-Krikken A, Lub-de Hooge MN, et al. (2009) Albumin-binding and tumor vasculature determine the antitumor effect of 15-deoxy-Delta-(12,14)-prostaglandin-J(2) in vivo. Neoplasia 11: 1348-1358.
31. Xin X, Yang S, Kowalski J, Gerritsen ME, (1999) Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 274: 9116-9121.
32. Bishop-Bailey D, Hla T, (1999) Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2. J Biol Chem 274: 17042-17048.
33. Tsuzuki T, Kawakami Y, (2008) Tumor angiogenesis suppression by {alpha}-eleostearic acid, a linolenic acid isomer with a conjugated triene system, via peroxisome proliferator-activated receptor {gamma}. Carcinogenesis.
34. Funovics P, Brostjan C, Nigisch A, Fila A, Grochot A, et al. (2006) Effects of 15d-PGJ(2) on VEGF-induced angiogenic activities and expression of VEGF receptors in endothelial cells. Prostaglandins Other Lipid Mediat 79: 230-244.
35. Dadras SS, Paul T, Bertoncini J, Brown LF, Muzikansky A, et al. (2003) Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 162: 1951-1960.
36. Shields JD, Borsetti M, Rigby H, Harper SJ, Mortimer PS, et al. (2004) Lymphatic density and metastatic spread in human malignant melanoma. Br J Cancer 90: 693-700.
37. Paulitschke V, Kunstfeld R, Gerner C (2010) From Molecular to Modular Tumor Therapy: Tumors are Reconstructible Communicatively Evolving Systems. Book chapter, Springer.
38. Meyer S, Vogt T, Landthaler M, Berand A, Reichle A, et al. (2009) Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma. PPAR Res 2009: 848645.
39. Paulitschke V, Kunstfeld R, Mohr T, Slany A, Micksche M, et al. (2009) Entering a new era of rational biomarker discovery for early detection of melanoma metastases: secretome analysis of associated stroma cells. J Proteome Res 8: 2501-2510.
40. Miyata Y, Chambraud B, Radanyi C, Leclerc J, Lebeau MC, et al. (1997) Phosphorylation of the immunosuppressant FK506-binding protein FKBP52 by casein kinase II: regulation of HSP90-binding activity of FKBP52. Proc Natl Acad Sci U S A 94: 14500-14505.
41. Tsutsumi S, Neckers L, (2007) Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis. Cancer Sci 98: 1536-1539.
42. Powers MV, Workman P, (2006) Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 13 (Suppl 1):: S125-135.
43. Gimenez Ortiz A, Montalar Salcedo J, (2010) Heat shock proteins as targets in oncology. Clin Transl Oncol 12: 166-173.
44. Banerji U, (2009) Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 15: 9-14.
45. Hanahan D, Weinberg RA, (2000) The hallmarks of cancer. Cell 100: 57-70.
46. Hofmeister V, Schrama D, Becker JC, (2008) Anti-cancer therapies targeting the tumor stroma. Cancer Immunol Immunother 57: 1-17.
47. Vandoros GP, Konstantinopoulos PA, Sotiropoulou-Bonikou G, Kominea A, Papachristou GI, et al. (2006) PPAR-gamma is expressed and NF-kB pathway is activated and correlates positively with COX-2 expression in stromal myofibroblasts surrounding colon adenocarcinomas. J Cancer Res Clin Oncol 132: 76-84.
48. Mueller BM, Romerdahl CA, Trent JM, Reisfeld RA, (1991) Suppression of spontaneous melanoma metastasis in scid mice with an antibody to the epidermal growth factor receptor. Cancer Res 51: 2193-2198.
49. Smalley KS, Brafford P, Haass NK, Brandner JM, Brown E, et al. (2005) Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. Am J Pathol 166: 1541-1554.
50. Schicher N, Paulitschke V, Swoboda A, Kunstfeld R, Loewe R, et al. (2009) Erlotinib and bevacizumab have synergistic activity against melanoma. Clin Cancer Res 15: 3495-3502.
51. Hoeller C, Pratscher B, Thallinger C, Winter D, Fink D, et al. (2005) Clusterin regulates drug-resistance in melanoma cells. J Invest Dermatol 124: 1300-1307.
52. Petzelbauer P, Bender JR, Wilson J, Pober JS, (1993) Heterogeneity of dermal microvascular endothelial cell antigen expression and cytokine responsiveness in situ and in cell culture. J Immunol 151: 5062-5072.
53. Hoeth M, Niederleithner H, Hofer-Warbinek R, Bilban M, Mayer H, et al. (2012) The Transcription Factor SOX18 Regulates the Expression of Matrix Metalloproteinase 7 and Guidance Molecules in Human Endothelial Cells. PLoS One 7: e30982.
54. Groger M, Niederleithner H, Kerjaschki D, Petzelbauer P, (2007) A previously unknown dermal blood vessel phenotype in skin inflammation. J Invest Dermatol 127: 2893-2900.
55. Hoeller C, Thallinger C, Pratscher B, Bister MD, Schicher N, et al. (2005) The non-receptor-associated tyrosine kinase Syk is a regulator of metastatic behavior in human melanoma cells. J Invest Dermatol 124: 1293-1299.
56. Lamprecht MR, Sabatini DM, Carpenter AE, (2007) CellProfiler: free, versatile software for automated biological image analysis. Biotechniques 42: 71-75.
57. Gerner C, Haudek-Prinz VJ, Lackner A, Losert A, Peter-Vorosmarty B, et al. (2010) Indications for cell stress in response to adenoviral and baculoviral gene transfer observed by proteome profiling of human cancer cells. Electrophoresis 31: 1822-1832.